ANIK - Anika Therapeutics, Inc.
| Previous Close | 37.28 |
| Open | 37.50 |
| Bid | 37.87 x 800 |
| Ask | 60.00 x 800 |
| Day's Range | 37.50 - 38.54 |
| 52 Week Range | 28.54 - 46.43 |
| Volume | 149,526 |
| Avg. Volume | 203,927 |
| Market Cap | 541.141M |
| Beta (3Y Monthly) | 1.56 |
| PE Ratio (TTM) | 18.64 |
| EPS (TTM) | 2.04 |
| Earnings Date | Feb 19, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.50 |
- Zacks•56 minutes ago
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
- Zacks•3 days ago
Guardant Health (GH) Looks Good: Stock Adds 6% in Session
Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
- Zacks•3 days ago
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
- Zacks•4 days ago
Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
- Zacks•5 days ago
OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session
OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Zacks•7 days ago
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
- Zacks•11 days ago
BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks•13 days ago
Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.
- Zacks•13 days ago
Twist Bioscience (TWST) Catches Eye: Stock Jumps 8%
Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks•14 days ago
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
- Business Wire•14 days ago
Anika to Showcase Regenerative Medicine and Orthobiologics Portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress being held in Cancun, Mexico ...
- Zacks•14 days ago
Will Anika Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Anika Therapeutics.
- Insider Monkey•17 days ago
Here’s What Hedge Funds Think About Anika Therapeutics, Inc. (ANIK)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- Business Wire•21 days ago
Anika to Participate in Two Investor Events in May 2019
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("
- Simply Wall St.•21 days ago
What You Must Know About Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Beta Value
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in Anika Therapeutics, Inc. (NASDAQ:ANIK), then you might want to consider its b...
Motley Fool•24 days agoAnika Therapeutics Inc (ANIK) Q1 2019 Earnings Call Transcript
ANIK earnings call for the period ending March 31, 2019.
- Zacks•24 days ago
Anika Therapeutics (ANIK) Q1 Earnings and Revenues Top Estimates
Anika (ANIK) delivered earnings and revenue surprises of 47.62% and 14.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•25 days ago
Anika: 1Q Earnings Snapshot
The Bedford, Massachusetts-based company said it had net income of 31 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- Business Wire•25 days ago
Anika Reports First Quarter 2019 Financial Results
Total Revenue Increased 16% Year-over-Year
- Business Wire•25 days ago
Anika Announces $50 Million Share Repurchase Program
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that its Board of Directors has authorized the repurchase of up to $50 million of the Company’s shares of common stock. Anika plans to purchase $30 million of shares under an accelerated share repurchase (ASR) program and $20 million of shares from time to time on the open market. “We are pleased to continue returning cash to shareholders through share repurchases, as we transform Anika into a global commercial company,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics.
- Business Wire•27 days ago
Anika Appoints Stephen Goldy as Vice President of U.S. Sales
Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S. Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Stephen Goldy to the newly created position of Vice President of U.S. Sales. Mr. Goldy brings over 20 years of experience developing and implementing sales strategy, with a specialization in the orthopedic, sports medicine and general surgery markets.
- Zacks•last month
Anika Therapeutics (ANIK) Reports Next Week: Wall Street Expects Earnings Growth
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•last month
Anika to Issue First-Quarter 2019 Financial Results and Business Highlights on Thursday, May 2
Anika Therapeutics, Inc. today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday, May 2, 2019, at 5:00 p.m.
- Simply Wall St.•2 months ago
Imagine Owning Anika Therapeutics (NASDAQ:ANIK) And Wondering If The 33% Share Price Slide Is Justified
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do b...
